Compare NSPR & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | DARE |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 33.4M |
| IPO Year | 2009 | 2014 |
| Metric | NSPR | DARE |
|---|---|---|
| Price | $0.72 | $2.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | 116.6K | ★ 136.9K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,310,000.00 | ★ $2,807,885.00 |
| Revenue This Year | $57.98 | $2,115.12 |
| Revenue Next Year | $95.41 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.27 |
| 52 Week High | $2.93 | $3.78 |
| Indicator | NSPR | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 48.77 |
| Support Level | $0.69 | $1.95 |
| Resistance Level | $1.04 | $2.24 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 68.23 | 43.48 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.